State laws and non-FDA-approved therapies: Florida SB 1768 in context

What Florida SB 1768 changes, and what it leaves alone

Florida SB 1768 took effect on July 1, 2025. It gives Florida-licensed MD and DO physicians a defined pathway to use certain non-FDA-approved stem cell therapies in three clinical areas, orthopedics, wound care, and pain management, provided the physician obtains informed consent and makes specific disclosures to the patient. The statute is written as a permission and disclosure framework for a physician's own conduct inside Florida, not as a product approval.

For a buying clinic, the practical effect is narrow. SB 1768 does not certify, approve, or endorse any specific product, manufacturer, or distributor. It does not change how a product is classified federally, how it must be processed, or what testing it must pass before it reaches a clinic. It changes what a Florida physician can document when choosing to use a non-FDA-approved therapy inside the three named specialties.

• What SB 1768 is: a state informed-consent and disclosure pathway for physician conduct in three named specialties
• What SB 1768 is not: a product approval, a safety finding, or a statement about any specific supplier

State permission and federal product status are two separate questions

Whether a Wharton's jelly product qualifies for the lighter-touch section 361 framework under 21 CFR 1271.10 is a determination for the clinic and its counsel, based on all applicable criteria in that regulation, not a determination a state statute can make.

For exosome and extracellular vesicle products, FDA has stated there are no FDA-approved exosome products. These are generally regulated as biologic drugs under section 351, and purchase and clinical-use decisions belong to the physician with their own regulatory counsel. Nothing in a state's own experimental-treatment statute changes that federal posture or substitutes for it.

What informed consent and disclosure typically involve

Florida SB 1768 requires informed consent and disclosures for specified physician uses. Ask counsel to confirm the exact applicable requirements.

Because statutory text and administrative interpretation can be amended independently of any distributor's literature, a clinic operating in Florida should confirm with its own counsel what current disclosure language needs to say, rather than relying on a supplier's summary of the statute.

Other states take different approaches, which matters for multi-location groups

Utah and Montana each maintain their own experimental-treatment statutes with their own scope and conditions. The existence of a Florida pathway says nothing about whether a comparable pathway exists, or exists on the same terms, in another state. A group with locations in multiple states should treat each state's statute as a separate legal question rather than assuming one state's framework transfers.

This is also why marketing that cites "state law allows this" without naming the specific state, statute, and scope is a flag rather than reassurance. The specifics vary enough between states that a general claim is not a substitute for reading the text that actually applies where a clinic operates.

What a purchasing decision still depends on

Regardless of which state permission exists, a buyer still needs the same documentation discipline: lot-level certificates of analysis, donor eligibility summaries, and a clear answer on how the supplier positions the product's regulatory category. State permission changes what a physician can consent a patient into; it does not supply any of that documentation.

This article is general information, not legal advice. Statute text, administrative rules, and FDA's own enforcement priorities can change. A clinic should confirm current requirements with its own FDA regulatory counsel before relying on any state statute as part of a purchasing or consent decision.